Entamoeba is a genus of single-celled parasites that live primarily in the intestinal tracts of humans and other vertebrates. Some species are completely harmless, while one, Entamoeba histolytica, causes a disease called amebiasis that affects an estimated 50 million people worldwide each year and kills roughly 100,000.
Basic Biology of Entamoeba
Entamoeba organisms are amoebae, meaning they lack a fixed shape and move by extending parts of their cell body. They belong to the group Archamoebea and were originally lumped together with free-living amoebae until researchers recognized that the intestinal species were biologically distinct enough to warrant their own genus.
Every intestinal Entamoeba species has two life stages: a trophozoite (the active, feeding form) and a cyst (the dormant, protective form). Trophozoites are shapeless cells with few visible internal structures beyond a nucleus and some small vacuoles. Cysts are tougher, encased in a protective wall, and can survive days to weeks outside the body. Because trophozoites and cysts look so similar across species under a microscope, scientists rely on just a few features to tell species apart: the size of the cyst, the number of nuclei inside a mature cyst (typically one, four, or eight), and the fine details of nuclear structure.
Species That Infect Humans
Several Entamoeba species can colonize the human gut, but only one is considered dangerous. E. histolytica is the pathogenic species, responsible for amebiasis. It can invade the intestinal wall and, in severe cases, spread to the liver, lungs, or brain. The remaining species that live in people, including E. coli, E. hartmanni, and E. polecki, are nonpathogenic. They feed on bacteria and food particles in the gut without causing tissue damage or symptoms.
One species, E. dispar, is nearly identical to E. histolytica under a microscope. For decades the two were considered the same organism, which created enormous confusion in diagnosis. A person could test positive for what looked like E. histolytica but actually harbor the harmless E. dispar. Modern molecular testing has largely solved this problem, but in many parts of the world, basic microscopy is still the only available tool, and the two species remain easy to confuse.
How Infection Spreads
Entamoeba infections follow a fecal-oral route. A person swallows mature cysts through contaminated water, food, or contact with unwashed hands. The cysts pass through the stomach unharmed and open up in the small intestine, releasing trophozoites that travel down to the large intestine. There, the trophozoites feed and multiply by dividing in two. Some eventually form new cysts, which leave the body in stool and can contaminate the environment again.
Cysts are the only infectious stage. Their thick walls protect them from stomach acid and allow them to persist in soil and water for weeks. Trophozoites, by contrast, die almost immediately once they leave the body and cannot survive the acidic environment of the stomach if swallowed. This is why the infection cycle depends entirely on the cyst form.
Standard chlorine levels used in municipal water treatment (around 2 to 5 parts per million) are not reliably effective against amoeba cysts in general. Boiling water or heating it above 65°C is a more dependable way to kill cysts, making it the recommended approach in areas where water safety is uncertain.
What Happens During Amebiasis
Most people infected with E. histolytica never develop symptoms. The trophozoites simply live in the intestinal cavity, and the person unknowingly passes cysts in their stool. These asymptomatic carriers are a key part of the transmission chain because they can spread the parasite without realizing they’re infected.
In a minority of cases, trophozoites begin invading the intestinal lining. This intestinal amebiasis typically causes bloody diarrhea, abdominal cramping, and pain that develops gradually over one to three weeks. It can mimic inflammatory bowel disease or bacterial dysentery, which sometimes leads to misdiagnosis.
In the most serious cases, trophozoites enter blood vessels in the intestinal wall and travel to other organs. The liver is the most common destination, where the parasites can form large abscesses. Less frequently, they reach the lungs or brain. Extraintestinal amebiasis can be life-threatening and requires prompt treatment.
How E. histolytica Destroys Tissue
E. histolytica has a distinctive method of attacking human cells. It first attaches to a cell using a surface protein called a lectin that locks onto specific sugar molecules on the host cell’s surface. This attachment is essential: if the sugar binding is blocked experimentally, the parasite can no longer kill cells even when forced into direct contact with them.
Once attached, the parasite doesn’t simply dissolve the host cell. Instead, it triggers the cell’s own self-destruct program, essentially tricking it into killing itself. This process involves a surge of calcium flooding into the target cell, which is irreversible and precedes death. After the host cell dies, the trophozoite engulfs and digests it. This attach-kill-eat cycle, repeated thousands of times, is what creates the ulcers and abscesses characteristic of amebiasis.
Diagnosis
Traditional microscopy, examining stool samples for cysts or trophozoites, is the most widely available diagnostic method but has significant limitations. It cannot distinguish E. histolytica from the harmless E. dispar, and false positives are common because several other intestinal protozoa can look similar under the microscope.
Antigen detection tests that identify E. histolytica-specific proteins in stool samples offer much better accuracy, with sensitivity reaching 100% and specificity around 95% in comparative studies. DNA-based testing using PCR is the most precise method available and can definitively separate E. histolytica from its look-alikes. In practice, the diagnostic approach depends on what’s available locally. Many clinics in high-burden regions still rely on microscopy, which means some infections are misidentified and some harmless species are unnecessarily treated.
Treatment
Amebiasis is treated in two phases. The first targets the active trophozoites causing tissue damage, typically with an antibiotic that also works against protozoa. Treatment for intestinal disease usually lasts 5 to 10 days. Liver abscesses require a similar course, and most respond well to medication alone without the need for drainage.
The second phase is just as important: eliminating cysts that remain in the intestinal lumen. The drugs that kill invasive trophozoites don’t effectively reach organisms sitting in the gut cavity, so a separate “luminal agent” is given afterward to clear remaining cysts and prevent relapse or continued transmission. Skipping this second step is a common reason infections recur.
People carrying nonpathogenic Entamoeba species like E. coli or E. hartmanni do not need treatment. These organisms cause no disease and require no intervention, which is another reason accurate species identification matters.
Who Is Most at Risk
Amebiasis is most common in tropical and subtropical regions with limited access to clean water and sanitation infrastructure. Travelers to endemic areas, people living in institutional settings with shared hygiene facilities, and men who have sex with men face elevated risk. In higher-income countries, most cases are imported, diagnosed in people who recently traveled to or immigrated from endemic regions. The global burden remains concentrated in South Asia, sub-Saharan Africa, and Central and South America, where contaminated water sources are the primary transmission route.